<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34496899</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1750-1172</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>16</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>Orphanet journal of rare diseases</Title>
          <ISOAbbreviation>Orphanet J Rare Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Methylphenidate for attention-deficit/hyperactivity disorder in patients with Smith-Magenis syndrome: protocol for a series of N-of-1 trials.</ArticleTitle>
        <Pagination>
          <StartPage>380</StartPage>
          <MedlinePgn>380</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">380</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13023-021-02003-z</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Smith-Magenis syndrome (SMS) is a rare genetic neurodevelopmental disorder characterized by intellectual disability and severe behavioural and sleep disturbances. Often, patients with SMS are diagnosed with attention-deficit/hyperactivity disorder (ADHD). However, the effectiveness of methylphenidate (MPH), the first-line pharmacological treatment for ADHD, in patients with SMS is unclear. Our objective is to examine the effectiveness of MPH for ADHD symptoms in individuals with SMS, proposing an alternative trial design as traditional randomized controlled trials are complex in these rare and heterogeneous patient populations.</AbstractText>
          <AbstractText Label="METHODS AND ANALYSIS">We will initiate an N-of-1 series of double-blind randomized and placebo-controlled multiple crossover trials in six patients aged ≥ 6 years with a genetically confirmed SMS diagnosis and a multidisciplinary established ADHD diagnosis, according to a power analysis based on a summary measures analysis of the treatment effect. Each N-of-1 trial consists of a baseline period, dose titration phase, three cycles each including randomized intervention, placebo and washout periods, and follow-up. The intervention includes twice daily MPH (doses based on age and body weight). The primary outcome measure will be the subscale hyperactivity/inattention of the Strengths and Difficulties Questionnaire (SDQ), rated daily. Secondary outcome measures are the shortened version of the Emotion Dysregulation Inventory (EDI) reactivity index, Goal Attainment Scaling (GAS), and the personal questionnaire (PQ). Statistical analysis will include a mixed model analysis. All subjects will receive an assessment of their individual treatment effect and data will be aggregated to investigate the effectiveness of MPH for ADHD in SMS at a population level.</AbstractText>
          <AbstractText Label="CONCLUSIONS">This study will provide information on the effectiveness of MPH for ADHD in SMS, incorporating personalized outcome measures. This protocol presents the first properly powered N-of-1 study in a rare genetic neurodevelopmental disorder, providing a much-needed bridge between science and practice to optimize evidence-based and personalized care.</AbstractText>
          <AbstractText Label="TRIAL REGISTRATION">This study is registered in the Netherlands Trial Register (NTR9125).</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Müller</LastName>
            <ForeName>A R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Advisium, 's Heeren Loo, Amersfoort, the Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zinkstok</LastName>
            <ForeName>J R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rommelse</LastName>
            <ForeName>N N J</ForeName>
            <Initials>NNJ</Initials>
            <AffiliationInfo>
              <Affiliation>Karakter, Child and Adolescent Psychiatry, Nijmegen, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatrics, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van de Ven</LastName>
            <ForeName>P M</ForeName>
            <Initials>PM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Data Science, Amsterdam University Medical Center, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roes</LastName>
            <ForeName>K C B</ForeName>
            <Initials>KCB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health Evidence, Biostatistics, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wijburg</LastName>
            <ForeName>F A</ForeName>
            <Initials>FA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Rooij-Askes</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Advisium, 's Heeren Loo, Amersfoort, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Linders</LastName>
            <ForeName>C</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Advisium, 's Heeren Loo, Amersfoort, the Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boot</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Advisium, 's Heeren Loo, Amersfoort, the Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>The Dalglish Family 22Q Clinic, University Health Network, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Eeghen</LastName>
            <ForeName>A M</ForeName>
            <Initials>AM</Initials>
            <Identifier Source="ORCID">0000-0001-8149-8645</Identifier>
            <AffiliationInfo>
              <Affiliation>Advisium, 's Heeren Loo, Amersfoort, the Netherlands. a.m.vaneeghen@amsterdamumc.nl.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, The Netherlands. a.m.vaneeghen@amsterdamumc.nl.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>NTR</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NTR9125</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Orphanet J Rare Dis</MedlineTA>
        <NlmUniqueID>101266602</NlmUniqueID>
        <ISSNLinking>1750-1172</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>207ZZ9QZ49</RegistryNumber>
          <NameOfSubstance UI="D008774">Methylphenidate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000697" MajorTopicYN="Y">Central Nervous System Stimulants</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008774" MajorTopicYN="Y">Methylphenidate</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058496" MajorTopicYN="Y">Smith-Magenis Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ADHD</Keyword>
        <Keyword MajorTopicYN="Y">Methylphenidate</Keyword>
        <Keyword MajorTopicYN="Y">Multiple crossover</Keyword>
        <Keyword MajorTopicYN="Y">N-of-1</Keyword>
        <Keyword MajorTopicYN="Y">Rare genetic neurodevelopmental disorder</Keyword>
        <Keyword MajorTopicYN="Y">Smith–Magenis syndrome</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>9</Day>
          <Hour>5</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34496899</ArticleId>
        <ArticleId IdType="pmc">PMC8424817</ArticleId>
        <ArticleId IdType="doi">10.1186/s13023-021-02003-z</ArticleId>
        <ArticleId IdType="pii">10.1186/s13023-021-02003-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Elsea SH, Williams SR. Smith–Magenis syndrome: Haploinsufficiency of RAI1 results in altered gene regulation in neurological and metabolic pathways. Expert Rev Mol Med. 2011;13:e14. doi: 10.1017/S1462399411001827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1462399411001827</ArticleId>
            <ArticleId IdType="pubmed">21545756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boot E, Linders CC, Tromp SH, van den Boogaard MJ, van Eeghen AM. Possible underreporting of pathogenic variants in RAI1 causing Smith–Magenis syndrome. Am J Med Genet A. 2021;20:126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8519085</ArticleId>
            <ArticleId IdType="pubmed">34089220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edelman EA, Girirajan S, Finucane B, Patel PI, Lupski JR, Smith ACM, et al.  Gender, genotype, and phenotype differences in Smith–Magenis syndrome: a meta-analysis of 105 cases. Clin Genet. 2007;71(6):540–550. doi: 10.1111/j.1399-0004.2007.00815.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1399-0004.2007.00815.x</ArticleId>
            <ArticleId IdType="pubmed">17539903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsea SH, Girirajan SS. Smith-Magenis syndrome. Eur J Hum Genet. 2008;16:412–421. doi: 10.1038/sj.ejhg.5202009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.ejhg.5202009</ArticleId>
            <ArticleId IdType="pubmed">18231123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laje G, Morse R, Richter W, Ball J, Pao M, Smith ACM. Autism spectrum features in Smith-Magenis syndrome. Am J Med Genet C Semin Med Genet. 2010;154C:456–462. doi: 10.1002/ajmg.c.30275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajmg.c.30275</ArticleId>
            <ArticleId IdType="pmc">PMC2967410</ArticleId>
            <ArticleId IdType="pubmed">20981775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poisson A, Nicolas A, Cochat P, Sanlaville D, Rigard C, De Leersnyder H, et al.  Behavioral disturbance and treatment strategies in Smith-Magenis syndrome. Orphanet J Rare Dis. 2015;10:111. doi: 10.1186/s13023-015-0330-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13023-015-0330-x</ArticleId>
            <ArticleId IdType="pmc">PMC4559928</ArticleId>
            <ArticleId IdType="pubmed">26336863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenberg F, Guzzetta V, De Oca-Luna RM, Magenis RE, Smith ACM, Richter SF, et al.  Molecular analysis of the Smith-Magenis syndrome: a possible contiguous-gene syndrome associated with del(17)(p11.2) Am J Hum Genet. 1991;49:1207–1218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1686451</ArticleId>
            <ArticleId IdType="pubmed">1746552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sloneem J, Oliver C, Udwin O, Woodcock KA. Prevalence, phenomenology, aetiology and predictors of challenging behaviour in Smith-Magenis syndrome. J Intellect Disabil Res. 2011;55:138–151. doi: 10.1111/j.1365-2788.2010.01371.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2788.2010.01371.x</ArticleId>
            <ArticleId IdType="pubmed">21199049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shayota BJ, Elsea SH. Behavior and sleep disturbance in Smith–Magenis syndrome. Curr Opin Psychiatry. 2019;32:73–78. doi: 10.1097/YCO.0000000000000474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/YCO.0000000000000474</ArticleId>
            <ArticleId IdType="pmc">PMC6362978</ArticleId>
            <ArticleId IdType="pubmed">30557269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shelley BP, Robertson MM. The neuropsychiatry and multisystem features of the Smith–Magenis Syndrome: a review. J Neuropsych Clin Neurosci. 2005;17:91–97. doi: 10.1176/jnp.17.1.91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/jnp.17.1.91</ArticleId>
            <ArticleId IdType="pubmed">15746488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fidler DJ, Hodapp RM, Dykens EM. Stress in families of young children with down syndrome, Williams syndrome, and Smith–Magenis syndrome. Early Educ Dev. 2000;122:60–66.</Citation>
        </Reference>
        <Reference>
          <Citation>Hodapp RM, Fidler DJ, Smith ACM. Stress and coping in families of children with Smith–Magenis syndrome. J Intellect Disabil Res. 1998;42:331–340. doi: 10.1046/j.1365-2788.1998.00148.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2788.1998.00148.x</ArticleId>
            <ArticleId IdType="pubmed">9828063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nag HE, Hoxmark LB, Nærland T. Parental experiences with behavioural problems in Smith–Magenis syndrome: the need for syndrome-specific competence. J Intellect Disabil. 2019;23:359–372. doi: 10.1177/1744629519847375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1744629519847375</ArticleId>
            <ArticleId IdType="pmc">PMC6734585</ArticleId>
            <ArticleId IdType="pubmed">31046579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laje G, Bernert R, Morse R, Pao M, Smith ACM. Pharmacological treatment of disruptive behavior in Smith–Magenis syndrome. Am J Med Genet C Semin Med Genet. 2010;154C:463–468. doi: 10.1002/ajmg.c.30282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajmg.c.30282</ArticleId>
            <ArticleId IdType="pmc">PMC3022344</ArticleId>
            <ArticleId IdType="pubmed">20981776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2004;24:24–29. doi: 10.1097/01.jcp.0000108984.11879.95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.jcp.0000108984.11879.95</ArticleId>
            <ArticleId IdType="pubmed">14709943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry. 2011;11:176. doi: 10.1186/1471-244X-11-176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-244X-11-176</ArticleId>
            <ArticleId IdType="pmc">PMC3229459</ArticleId>
            <ArticleId IdType="pubmed">22074258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165:1475–1488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC81663</ArticleId>
            <ArticleId IdType="pubmed">11762571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheon KA, Ryu YH, Kim JW, Cho DY. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol. 2005;15:95–101. doi: 10.1016/j.euroneuro.2004.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.euroneuro.2004.06.004</ArticleId>
            <ArticleId IdType="pubmed">15572278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Poest CE, Jansen FE, Braun KPJ, Peters JM. Update on drug management of refractory epilepsy in tuberous sclerosis complex. Pediatr Drugs. 2020;22:73–78. doi: 10.1007/s40272-019-00376-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40272-019-00376-0</ArticleId>
            <ArticleId IdType="pubmed">31912454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Kuijper G, Evenhuis H, Minderaa RB, Hoekstra PJ. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. J Intellect Disabil Res. 2014;58:71–83. doi: 10.1111/j.1365-2788.2012.01631.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2788.2012.01631.x</ArticleId>
            <ArticleId IdType="pubmed">23046144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradbury J, Avila C, Grace S. Practice-based research in complementary medicine: could N-of-1 trials become the new gold standard? Healthcare. 2020;8:15. doi: 10.3390/healthcare8010015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/healthcare8010015</ArticleId>
            <ArticleId IdType="pmc">PMC7151123</ArticleId>
            <ArticleId IdType="pubmed">31936355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520:609–611. doi: 10.1038/520609a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/520609a</ArticleId>
            <ArticleId IdType="pubmed">25925459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018;109:952–963. doi: 10.1016/j.fertnstert.2018.05.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.fertnstert.2018.05.006</ArticleId>
            <ArticleId IdType="pmc">PMC6366451</ArticleId>
            <ArticleId IdType="pubmed">29935653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol. 2011;64:1085–1094. doi: 10.1016/j.jclinepi.2010.12.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jclinepi.2010.12.019</ArticleId>
            <ArticleId IdType="pubmed">21530171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tate RL, Perdices M. Single-case experimental designs for clinical research and neurorehabilitation settings: Planning, conduct, analysis, and reporting. Routledge. 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Guyatt G, Sackett D, Adachi J, Roberts R, Chong J, Rosenbloom D, et al.  A clinician’s guide for conducting randomized trials in individual patients. CMAJ. 1988;139:497–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1268200</ArticleId>
            <ArticleId IdType="pubmed">3409138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shamseer L, Sampson M, Bukutu C, Schmid CH, Nikles J, Tate R, et al.  CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration. BMJ. 2015;350:h1793. doi: 10.1136/bmj.h1793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.h1793</ArticleId>
            <ArticleId IdType="pubmed">25976162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. 2011. http://www.cebm.net/index.aspx?o=5653. Accessed 8 Feb 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Porcino AJ, Shamseer L, Chan AW, Kravitz RL, Orkin A, Punja S, et al.  SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ. 2020;368:m122. doi: 10.1136/bmj.m122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.m122</ArticleId>
            <ArticleId IdType="pubmed">32107202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell GK, Hardy JR, Nikles CJ, Carmont SAS, Senior HE, Schluter PJ, et al.  The effect of methylphenidate on fatigue in advanced cancer: an aggregated N-of-1 trial. J Pain Symptom Manag. 2015;50:289–296. doi: 10.1016/j.jpainsymman.2015.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpainsymman.2015.03.009</ArticleId>
            <ArticleId IdType="pubmed">25896104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swanson JM, Volkow ND. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res. 2002;130:73–78. doi: 10.1016/S0166-4328(01)00433-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0166-4328(01)00433-8</ArticleId>
            <ArticleId IdType="pubmed">11864720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazefsky CA, Yu L, White SW, Siegel M, Pilkonis PA. The emotion dysregulation inventory: psychometric properties and item response theory calibration in an autism spectrum disorder sample. Autism Res. 2018;11:928–941. doi: 10.1002/aur.1947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/aur.1947</ArticleId>
            <ArticleId IdType="pmc">PMC6026073</ArticleId>
            <ArticleId IdType="pubmed">29624893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaasterland CMW, Van Der Weide MCJ, Roes KCB, Van Der Lee JH. Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation. BMC Med Res Methodol. 2019;19:227. doi: 10.1186/s12874-019-0866-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12874-019-0866-x</ArticleId>
            <ArticleId IdType="pmc">PMC6894223</ArticleId>
            <ArticleId IdType="pubmed">31801463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elliott R, Wagner J, Sales CMD, Rodgers B, Alves P, Café MJ. Psychometrics of the personal questionnaire: a client-generated outcome measure. Psychol Assess. 2016;28:263–278. doi: 10.1037/pas0000174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1037/pas0000174</ArticleId>
            <ArticleId IdType="pubmed">26075406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman R, Meltzer H, Bailey V. The Strengths and Difficulties Questionnaire: a pilot study on the validity of the self-report version. Int Rev Psychiatry. 2003;15:173–177. doi: 10.1080/0954026021000046137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/0954026021000046137</ArticleId>
            <ArticleId IdType="pubmed">12745329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazefsky CA, Yu L, Pilkonis PA. Psychometric properties of the emotion dysregulation inventory in a nationally representative sample of youth. J Clin Child Adolesc Psychol. 2020;7:1–13. doi: 10.1080/15374416.2019.1703710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15374416.2019.1703710</ArticleId>
            <ArticleId IdType="pmc">PMC7781089</ArticleId>
            <ArticleId IdType="pubmed">31910035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall CL, Guo B, Valentine AZ, Groom MJ, Daley D, Sayal K, et al.  The validity of the Strengths and Difficulties Questionnaire (SDQ) for children with ADHD symptoms. PLoS ONE. 2019;14:e0218518. doi: 10.1371/journal.pone.0218518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0218518</ArticleId>
            <ArticleId IdType="pmc">PMC6583960</ArticleId>
            <ArticleId IdType="pubmed">31216327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaptein S, Jansen DEMC, Vogels AGC, Reijneveld SA. Mental health problems in children with intellectual disability: use of the Strengths and Difficulties Questionnaire. J Intellect Disabil Res. 2008;52:125–131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18197951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tate RL, Perdices M, Rosenkoetter U, Wakim D, Godbee K, Togher L, et al.  Revision of a method quality rating scale for single-case experimental designs and n-of-1 trials: the 15-item Risk of Bias in N-of-1 Trials (RoBiNT) Scale. Neuropsychol Rehabil. 2013;23:619–638. doi: 10.1080/09602011.2013.824383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09602011.2013.824383</ArticleId>
            <ArticleId IdType="pubmed">24050810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Methylphenidate (MPH): physician’s guide to prescribing. Cited 9 Mar 2021. www.methylphenidate-guide.eu.</Citation>
        </Reference>
        <Reference>
          <Citation>Senn S. Sample size considerations for n-of-1 trials. Stat Methods Med Res. 2019;28:372–383. doi: 10.1177/0962280217726801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0962280217726801</ArticleId>
            <ArticleId IdType="pubmed">28882093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matthijssen AFM, Dietrich A, Bierens M, Kleine Deters R, Van De Loo-Neus GHH, Van Den Hoofdakker BJ, et al.  Effects of discontinuing methylphenidate on strengths and difficulties, quality of life and parenting stress. J Child Adolesc Psychopharmacol. 2020;30:159–165. doi: 10.1089/cap.2019.0147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/cap.2019.0147</ArticleId>
            <ArticleId IdType="pubmed">31880479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muris P, Meesters C, Van den Berg F. The Strengths and Difficulties Questionnaire (SDQ) further evidence for its reliability and validity in a community sample of Dutch children and adolescents. Eur Child Adolesc Psychiatry. 2003;12:1–8. doi: 10.1007/s00787-003-0298-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00787-003-0298-2</ArticleId>
            <ArticleId IdType="pubmed">12601558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>m-Path. Cited 9 Mar 2021. www.m-Path.io.</Citation>
        </Reference>
        <Reference>
          <Citation>Müller AR, Brands MM, van de Ven PM, Roes KC, Cornel MC, van Karnebeek CD, et al.  The power of 1: systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders. Neurology. 2021;96:529–540. doi: 10.1212/WNL.0000000000011597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000011597</ArticleId>
            <ArticleId IdType="pmc">PMC8032375</ArticleId>
            <ArticleId IdType="pubmed">33504638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT. The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med. 1990;112:293–299. doi: 10.7326/0003-4819-112-4-293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-112-4-293</ArticleId>
            <ArticleId IdType="pubmed">2297206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stunnenberg BC, Deinum J, Nijenhuis T, Huysmans F, van der Wilt GJ, van Engelen BGM, et al.  N-of-1 trials: evidence-based clinical care or medical research that requires IRB approval? A practical flowchart based on an ethical framework. Healthcare. 2020;8:49. doi: 10.3390/healthcare8010049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/healthcare8010049</ArticleId>
            <ArticleId IdType="pmc">PMC7151074</ArticleId>
            <ArticleId IdType="pubmed">32120865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What ever happened to N-of-1 trials? Insiders’ perspectives and a look to the future. Milbank Q. 2008;86:533–555. doi: 10.1111/j.1468-0009.2008.00533.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-0009.2008.00533.x</ArticleId>
            <ArticleId IdType="pmc">PMC2690377</ArticleId>
            <ArticleId IdType="pubmed">19120979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Backman CL, Harris SR. Case studies, single-subject research, and N of 1 randomized trials: comparisons and contrasts. Am J Phys Med Rehabil. 1999;78:170–176. doi: 10.1097/00002060-199903000-00022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00002060-199903000-00022</ArticleId>
            <ArticleId IdType="pubmed">10088595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaasterland CMW, Jansen-van der Weide MC, Vroom E, Leeson-Beevers K, Kaatee M, Kaczmarek R, et al.  The POWER-tool: recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. Health Policy (New York) 2018;122:1287–1294. doi: 10.1016/j.healthpol.2018.09.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.healthpol.2018.09.011</ArticleId>
            <ArticleId IdType="pubmed">30274934</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
